Caas Capital Management LP Biomarin Pharmaceutical Inc Call Options Transaction History

Caas Capital Management LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $381,392 - $441,320	4,400 New	4,400 $381,000
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $1.87 Million - $2.27 Million	-25,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $1.82 Million - $2.26 Million	25,000 New	25,000 $2.19 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.